HUP0303545A3 - Tumor proliferation inhibitors and parmaceutical compositions containing them - Google Patents

Tumor proliferation inhibitors and parmaceutical compositions containing them

Info

Publication number
HUP0303545A3
HUP0303545A3 HU0303545A HUP0303545A HUP0303545A3 HU P0303545 A3 HUP0303545 A3 HU P0303545A3 HU 0303545 A HU0303545 A HU 0303545A HU P0303545 A HUP0303545 A HU P0303545A HU P0303545 A3 HUP0303545 A3 HU P0303545A3
Authority
HU
Hungary
Prior art keywords
compositions containing
tumor proliferation
proliferation inhibitors
parmaceutical
parmaceutical compositions
Prior art date
Application number
HU0303545A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of HUP0303545A2 publication Critical patent/HUP0303545A2/hu
Publication of HUP0303545A3 publication Critical patent/HUP0303545A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
HU0303545A 2000-10-06 2001-09-28 Tumor proliferation inhibitors and parmaceutical compositions containing them HUP0303545A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23871200P 2000-10-06 2000-10-06
PCT/US2001/042405 WO2002028874A2 (en) 2000-10-06 2001-09-28 Tumor proliferation inhibitors

Publications (2)

Publication Number Publication Date
HUP0303545A2 HUP0303545A2 (hu) 2004-03-01
HUP0303545A3 true HUP0303545A3 (en) 2004-03-29

Family

ID=22899014

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0303545A HUP0303545A3 (en) 2000-10-06 2001-09-28 Tumor proliferation inhibitors and parmaceutical compositions containing them

Country Status (7)

Country Link
US (2) US6653290B2 (hu)
EP (1) EP1326875A2 (hu)
JP (1) JP2004518633A (hu)
AU (1) AU2002211834A1 (hu)
CA (1) CA2425264A1 (hu)
HU (1) HUP0303545A3 (hu)
WO (1) WO2002028874A2 (hu)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653290B2 (en) * 2000-10-06 2003-11-25 Bristol-Myers Squibb Company Tumor proliferation inhibitors
US7241779B2 (en) 2003-12-23 2007-07-10 Cephalon, Inc. Fused pyrrolocarbazoles
US7169802B2 (en) 2003-12-23 2007-01-30 Cephalon, Inc. Fused pyrrolocarbazoles
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
US7846945B2 (en) * 2007-03-08 2010-12-07 Lexicon Pharmaceuticals, Inc. Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
CN104016992B (zh) 2008-11-19 2017-04-12 赛福伦公司 吲唑并[5,4‑a]吡咯并[3,4‑c]咔唑化合物的形式

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552842A (en) 1983-01-28 1985-11-12 Bristol-Myers Company Process for producing rebeccamycin
US4487925A (en) 1983-01-28 1984-12-11 Bristol-Myers Company Rebeccamycin and process for its preparation
US4567143A (en) 1984-09-04 1986-01-28 Bristol-Myers Company Process for preparing 4'-deschlororebeccamycin
US4785085A (en) 1986-11-21 1988-11-15 Bristol-Myers Company Rebeccamycin analogs
WO1989007105A1 (en) 1988-02-04 1989-08-10 Kyowa Hakko Kogyo Co., Ltd. Staurosporin derivatives
DE3803620A1 (de) 1988-02-06 1989-08-17 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittel
DE3924538A1 (de) 1989-07-25 1991-01-31 Goedecke Ag Indolocarbazol und dessen verwendung
US5618809A (en) 1989-12-14 1997-04-08 Schering Corporation Indolocarbazoles from saccharothrix aerocolonigenes copiosa subsp. nov SCC 1951 ATCC 53856
IL97233A (en) 1990-03-06 1995-03-30 Bristol Myers Squibb Co Analogs of rabamycin, their manufacture and pharmaceutical preparations containing them
US5478813A (en) 1990-05-11 1995-12-26 Banyu Pharmaceutical Co., Ltd. Antitumor substance BE-13793C derivatives
US5668271A (en) 1991-11-29 1997-09-16 Banyu Pharmaceutical Co., Ltd. Indolopyrrolocarbazole derivatives
US5589365A (en) 1991-11-29 1996-12-31 Banyu Pharmaceutical Co., Ltd. Process for producing glycosylated indolopyrrolocarbazole derivatives by culturing certain microorganisms
NZ245203A (en) 1991-11-29 1997-07-27 Banyu Pharma Co Ltd 5h-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6h)-dione derivatives substituted in position-13 by a pentose or hexose group; corresponding indolo-furano(anhydride)intermediates
EP0630898B1 (en) 1992-09-21 2001-11-28 Kyowa Hakko Kogyo Co., Ltd. Thrombocytopenia remedy
FR2696465B1 (fr) 1992-10-02 1994-12-23 Adir Nouveaux dérivés d'ellipticine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
JP3603322B2 (ja) 1992-12-14 2004-12-22 萬有製薬株式会社 インドロピロロカルバゾール誘導体の製造法
US5468872A (en) 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
WO1995030682A1 (fr) 1994-05-09 1995-11-16 Banyu Pharmaceutical Co., Ltd. Derive d'indolopyrolocarbazole antitumoral
AU3086495A (en) 1994-08-02 1996-03-04 Banyu Pharmaceutical Co., Ltd. Antitumor indolopyrrolocarbazoles
US5475110A (en) 1994-10-14 1995-12-12 Cephalon, Inc. Fused Pyrrolocarbazoles
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
AU6888196A (en) 1995-08-11 1997-03-12 Yale University Glycosylated indolocarbazole synthesis
IL127918A0 (en) * 1996-08-22 1999-11-30 Bristol Myers Squibb Co Novel amino sugar and related sugar derivatives of indolylopyrrolocarbazoles their use as antitumor agents and pharmaceutical formulations
CO4940430A1 (es) 1997-07-07 2000-07-24 Novartis Ag Compuestos policiclicos que contienen estaurosporina hidrogenada con propiedades farmacologicas convenientes y un efecto inhibidor sobre el crecimiento de las celulas tumorales
FR2801054B1 (fr) 1999-11-17 2003-06-13 Adir Nouveaux derives de 12,13-(pyranosyl)-indolo[2,3-a]pyrrolo [3,4-c]carbazole et 12,13-(pyranosyl)-furo[3,4-c]indolo [2,3-a]carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6653290B2 (en) * 2000-10-06 2003-11-25 Bristol-Myers Squibb Company Tumor proliferation inhibitors

Also Published As

Publication number Publication date
WO2002028874A3 (en) 2002-10-31
EP1326875A2 (en) 2003-07-16
AU2002211834A1 (en) 2002-04-15
US6653290B2 (en) 2003-11-25
HUP0303545A2 (hu) 2004-03-01
CA2425264A1 (en) 2002-04-11
JP2004518633A (ja) 2004-06-24
US20030203860A1 (en) 2003-10-30
WO2002028874A2 (en) 2002-04-11
US20020068705A1 (en) 2002-06-06
US7138377B2 (en) 2006-11-21

Similar Documents

Publication Publication Date Title
AU6147401A (en) Compositions and methods for the treatment of cancer
HUP0303494A3 (en) Parmaceutical compositions containing bacterial gyrase inhibitors and uses thereof
EP1311551A4 (en) COMPOSITIONS AND METHODS FOR BIOACTIVE COATING
AU2002357119A8 (en) Mitocidal compositions and methods
AU5160201A (en) Compositions comprising natural agents for treatment of cancer
AU9684601A (en) Compositions that inhibit proliferation of cancer cells
PL352931A1 (en) Compositions and uses of et743 for treating cancer
HUP0400609A3 (en) Wet-skin treatment compositions
EP1509539A4 (en) COMPOSITIONS AND METHODS RELATING TO CANCER
AU6395201A (en) Tumour suppressor and uses thereof
EP1424897A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
AU2002357748A8 (en) Osteopontin-related compositions and methods
AU2002341749A1 (en) Methods and compositions for inhibiting the proliferation of prostate cancer cells
HUP0402341A3 (en) Compositions containing thiazol-2-ylamines for the treatment of cancer
HUP0303545A3 (en) Tumor proliferation inhibitors and parmaceutical compositions containing them
GB0108886D0 (en) Conductor composition II
EP1469870A4 (en) NEW COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
GB0009609D0 (en) Therapeutic compositions
AU2002366900A8 (en) Allocation of real time files
IL154354A0 (en) Composition for prophylaxis and treatment of cancer
GB0030857D0 (en) Therapeutic compositions
EP1587405A4 (en) NEW COMPOSITIONS AND METHODS OF CANCER
AU2003298708A8 (en) Gpc99 and gpc99a: methods and compositions for treating cancer
EP1370576A4 (en) METHODS AND COMPOSITIONS FOR MODULATING TUMOR REMOVAL
EP1287362A4 (en) COMPOSITIONS AND METHODS FOR MODULATING TUMOR SPECIFIC EXPRESSION

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees